Dyslipidemia Concept Map | Pathophysiology | Etiology | Treatment | Cholesterol Lowering Drugs
![]() |
Dyslipidemia Concept Map Order the full map |
Dyslipidemia (Hyperlipidemia) Concept Map: An Overview
The aim of this map is to cover the pharmacotherapy of dyslipidemia in an easy and an interesting way that will help you understand the topic and link it with the other related cardiovascular diseases as atherosclerosis. Look inside the map and understand it through this video.EXPLANATION VIDEO
DEFINITION
The concept map of Dyslipidemia
(Hyperlipidemia) starts with the definition.
Dyslipidemia is a disorder of elevated or abnormal levels of lipids
and/or lipoproteins in the blood, characterized by high cholesterol,
triglycerides (TGs), or both, or low High-density lipoprotein (HDL) level.
From this definition branches out
the normal physiology of lipid metabolism including what is meant by
lipoproteins, function of lipoproteins, and their classification. Low-density
lipoproteins (LDL); carry cholesterol from the liver to cells of the body; it
is referred to as the "bad cholesterol" lipoprotein. LDL has a role in initiating the
atherosclerosis process; this is how dyslipidemia is a risk factor for atherosclerosis
and consequently cardiovascular diseases (a small map for cardiovascular
diseases categories is included).
LIPID METABOLISM (Normal Physiology)
In this map lipid metabolism is
explained briefly through the following diagram:
The intestine absorbs dietary fat
and packages it into chylomicrons, which are transported to peripheral tissues
through the blood. The enzyme
lipoprotein lipase breaks down chylomicrons; and fatty acids enter muscle and
adipose tissues. The chylomicron remnants are subsequently taken up by the
liver to start the process of very-low-density lipoproteins (VLDLs)
synthesis. The liver secretes VLDL,
which undergo lipolysis by lipoprotein lipase to form LDLs. LDLs are then taken up by the liver and by the
peripheral tissues. HDL is produced by
the liver. Its function is to transport
cholesterol from the body back to the liver.
That is why it is called “good cholesterol” lipoprotien.
CLINICAL PRESENTATION
Most patients are asymptomatic
for many years prior to the appearance of physical findings.
Physical findings can include:
- corneal arcus of the eye and
- tuberous xanthomas in the Achilles tendon, hands, feet, elbows, and/or knees.
And symptoms of dyslipidemia can
include: paresthesias, dypsnea, and confusion.
CLASSIFICATION
Primary
Dyslipidemia; occurs due to genetic mutations; it affects lipoprotein
synthesis and metabolism causing the following lipid disorders:
Isolated
hypercholesterolemia (increase in cholesterol only)
-
Familial
hypercholesterolemia (FH)
-
Familial defective apoB-100
(FDB)
-
Polygenic
hypercholesterolemia
Isolated hypertriglyceridemia
(increase in TGs only)
-
Familial
hypertriglyceridemia (FHTG)
-
Lipoprotein lipase (LPL)
deficiency
-
Familial apoC-II deficiency
Mixed or combined
hyperlipidemias (increase in both cholesterol and TGs)
-
Familial combined
hyperlipidemia (FCHL)
-
Familial
dysbetalipoproteinemia (FDBL)
Watch the video to know when
Primary Dyslipidemia is suspected in a patient.
On the other hand, Secondary Dyslipidemia can be caused by the
following:
- Diseases: diabetes, hypothyrodism, obstructive liver disease/
biliary cirrhosis, renal disease, nephrotic syndrome/ chronic
renal failure, or obesity.
- Drugs: estrogen, progestins, protease inhibitors, anabolic steroids, corticosteroids, isotretinoin, cyclosporine, atypical antipsychotics, thiazide diuretics, or β-Blockers.
These causes should be considered
in the diagnosis and the management of dyslipidemia.
RISK FACTORS
Dyslipidemia risk factors are classified as:
- Positive Risk Factors
- Negative Risk Factors
- Emerging Risk Factors
Details are available in the
video above.
DIAGNOSIS
Diagnosis of dyslipidemia is
based on the Fasting Lipid Profile of the patient; accompanied by the assessment
of cardiovascular risk factors using Framingham Risk Score for patients
with ≥2 risk factors.
Three
Categories of Risk that Modify LDL-Cholesterol Goals (details are
included in the map/video):
1-
CHD and CHD Risk
Equivalents.
2-
For patients with ≥2 risk
factors, perform Framingham 10-year CHD risk assessment.
3-
For patients with ≤1 risk
factor, 10-year risk assessment is not required.
These risk categories are linked
to (treatment goals) part in the map.
TREATMENT
This part of the map starts with dyslipidemia treatment goals (classified according to
the risk category) and targets (primary target
for therapy is LDL).
Therapeutic
Lifestyle Changes (TLC) and dietary recommendations are stated under the
part of non-pharmacological treatment of dyslipidemia.
Pharmacological treatment of dyslipidemia includes:
Four classes of lipid-lowering drugs:
- the 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors (the "statins"), including; atorvastatin, fluvastatin, lovastatin, pravastatin, rosuvastatin, simvastatin, and pitavastatin
- the fibrates (gemfibrozil and fenofibrate),
- niacin/nicotinic acid, and
- the bile acid binding resins (colestipol, colesevelam, and cholestyramine)
In addition to;
- the cholesterol absorption inhibitor, Ezetimibe, and
- Omega-3 fatty acids (fish oils)
Each drug / drug class has its
own map that covers: the mechanism of action, indications, adverse effects,
drug interactions, contraindications, and precautions if any. The map also shows you how
to manage certain adverse effects and drug interactions for these drugs. See the following example for Bile acid sequestrants.
![]() |
Bile Acid Sequestrants Click to enlarge |
Dyslipidemia Folded Poster |
We hope you find Dyslipidemia Concept Map helpful and we are looking forward to hearing your opinion. This map is available in the following formats:
Map's Format
|
Delivery
|
Printing
|
|
Folded Poster
The maps is printed out on ordinary A1 size paper and it is folded to be nearly sized as A4 paper.
|
Physical.
To be sent to your address through the Egyptian Registered Postal Mail.
Delivery in Egypt takes few days,
Other countries: 2-3 weeks; you can upgrade to express mail. Please contact us for details.
|
Already printed out.
|
|
Whole Map
It's the map's soft copy. You will have the map as a whole on your computer screen.
|
Electornic; Download link.
A .pdf file for the whole map will be available for download immediately after payment received.
|
Printing the .pdf file of the map is not allowed.
|
Buy Now |
Printable Version
The map is split into pages to be printed on nine A4 papers. After printing them, you have to tape the edges together to make a folded poster.
|
Electornic; Download link.
A .pdf file for the printable version of the map will be available for download immediately after payment received.
|
Printing is allowed. The map is to be printed out on several pages.
|
Buy Now |
Dyslipidemia concept map is written by: May Mehanna, BCPS
Reviewed and edited by Maha Atef, B Pharm.
Last updated on: 11 January 2013
Last updated on: 11 January 2013
![]() |
Back to Diseases and Conditions |
bile acid sequestrants
cholesterol lowering drugs mind map
Diagnosis
dyslipidemia concept map
fibrates
pharmacists education
pharmacotherapy of dyslipidemia
statins
Treatment of dyslipidemai
4 comments